Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87533 | 0.71 | — | — | |
| SCHEMBL1389231 | 0.69 | HSP90AA1 (0.42) | — | |
| SCHEMBL28232834 | 0.67 | NPC1 (0.31) | — | |
| SCHEMBL219657 | 0.65 | KDM4E (0.50) | — | |
| SCHEMBL5056726 | 0.65 | — | — | |
| SCHEMBL15135194 | 0.65 | IMPDH2 (0.37) | — | |
| SCHEMBL20523585 | 0.64 | — | — | |
| SCHEMBL21013636 | 0.63 | NOS1 (0.33) | — | |
| SCHEMBL13078874 | 0.62 | METAP2 (0.32) | — | |
| SCHEMBL539031 | 0.62 | FBP1 (0.32) | FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275088-B2 | Method for producing granules | TAKEDA PHARMACEUTICALS CO (JP) | 2018-09-26 | — | — | EP | disclosed |
| EP-2275088-B1 | Method for producing granules | TAKEDA PHARMACEUTICAL (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-9011926-B2 | Method for producing granules | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-21 | — | — | US | disclosed |
| US-20150072015-A1 | METHOD FOR PRODUCING GRANULES | TAKEDA PHARMACEUTICAL (JP) | 2015-03-12 | — | — | US | disclosed |
| US-8871273-B2 | Method for producing granules | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-28 | — | — | US | disclosed |
| EP-2275088-A2 | Method for producing granules | Takeda Pharmaceutical Company Limited (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20080152640-A1 | Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080138427-A1 | Reduced variation in the dissolution profile of a biologically active substance; pharmaceutical, drug sprayed while spraying a binding liquid to the cores; centrifugal fluidized bed coating granulation machine set to1.5 g/cm2 | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1852100-A1 | METHOD FOR PRODUCING GRANULES | Takeda Pharmaceutical Company Limited (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-6248919-B1 | E.G., (2S)-2-(((5-((BUTYL(2-CYCLOHEXYLETHYL)AMINO)METHYL) -2'-METHYL(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-4-(METHYLSULFAN YL)BUTANOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR PRODRUG THEREOF. | ABBOTT LABORATORIES | 2001-06-19 | — | — | US | disclosed |
| US-6242494-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS, DIABETIC RETINOPATHY, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2001-06-05 | — | — | US | disclosed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | disclosed |
| US-5089489-A | Enzyme inhibitors | FARMITALIA CARLO ERBA S.R.L. (IT) | 1992-02-18 | — | — | US | disclosed |
| US-4954493-A | ENZYME INHIBITORS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152640-A1 | Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer | ABCB1, ABCB11, SLC47A2 | FBP1 2133/4885 |
| US-20080138427-A1 | Reduced variation in the dissolution profile of a biologically active substance; pharmaceutical, drug sprayed while spraying a binding liquid to the cores; centrifugal fluidized bed coating granulation machine set to1.5 g/cm2 | SERPINA6, CMA1, CRH | FBP1 3638/4885 |
| US-20150072015-A1 | METHOD FOR PRODUCING GRANULES | SERPINA6, GCG, GRN | FBP1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.